AbbVie Pharmaceuticals has recently completed the merger of Allergan to become the fourth largest pharmaceutical company in the world. Left, AbbVie Pharmaceuticals Taiwan Branch General Manager Raima Wei, right, Allergan Medical Cosmetics General Manager Shangwei Lin. Photo: Courtesy of AbbVie
In addition to the new coronavirus vaccine and drug development, the recent merger between AbbVie and Allergan, an Irish company, has been the center of attention in this year's pharmaceutical industry news. Because this merger amounted to as much as 63 billion dollars, and AbbVie has more than 10 years of global drug sales champion of biopharmaceuticals, Allergan has a well-known botulinum injections, including a number of medical aesthetic first brand products.
AbbVie jumps up the rankings to lead in immunology, hepatitis C, and medical aesthetics
The combined company has more than 30 products covering more than 60 conditions. It is No. 1 globally in immunology, hepatitis C and aesthetics, No. 2 in blood cancers, and a leader in ophthalmology and women's healthcare. As a result of its expansion, AbbVie has jumped from the ninth largest pharmaceutical company in the world to the fourth. In Taiwan, AbbVie has risen from thirteenth to the top ten.
AbbVie used to be the western pharmaceutical division of Abbott, but seven and a half years ago, it was spun off from Abbott, and its performance has been highly publicized. It has been recognized with three golds and two silvers in the National Biotechnology and Healthcare Quality Award, which is known as the Oscar of biotechnology and healthcare in China, and it has actively demonstrated its strength in innovative drug discovery and development and its determination to make a difference. The company has been actively promoting new drug launches and clinical trials in Taiwan, with more than 60 clinical trials currently underway in various medical centers in Taiwan. The company has also been recognized as one of the best employers at home and abroad.
Allergan is a leader in medical aesthetics, and the merger of two major pharmaceutical companies spells a diversified way out
Allergan's classic ace drug, Botox injections, will have a global production volume of more than 100 million vials by (2019). In addition to being a leader in medical aesthetics, it is approved for use in 11 indications in the specialty medical field, covering chronic migraines, spasticity, strabismus, and overactive bladder, among others.
Allergan has world-class medical aesthetics, as well as ophthalmology, gastrointestinal and central nervous system therapies. AbbVie, on the other hand, has strong R&D and commercial capabilities, and an international reach across 175 countries. The merger offers both companies a way out of the challenge of relying too heavily on a single star seller for revenue. The two companies are working on a number of new product groups, and we'll be watching closely to see where they go from here.
AbbVie Pharmaceuticals Taiwan General Manager Raima Wei noted that the new AbbVie after the merger will focus on immunology, oncology, virology, ophthalmology, neurology, aesthetics, gastroenterology, women's health, and other specialty areas.
After the merger, therapeutic areas will be handled by AbbVie, and the ophthalmology and neuroscience teams that were part of Allergan will be integrated into AbbVie. Allergan Medical Aesthetics will operate independently. Weirima further explained that because the Allergan brand name is so well established in the minds of consumers/patients and healthcare professionals in both the aesthetic and ophthalmic fields, the ophthalmology and medical aesthetics will continue to be marketed under the Allergan name.
Mr. Sean Lin, General Manager of Allergan Medical Aesthetics in Taiwan and Hong Kong, said that Allergan's medical aesthetic products are well known around the world. We will continue to develop new treatments and equipment, focusing on caring for skin conditions, eliminating fat, addressing facial lines and fillers, and continue to strive to differentiate our services to our customers and strengthen our position as a leader in the field of medical aesthetics.
Join us for daily attention to your health! LINE@ ID:@ Subscribe to the Healthy Lovejoy AV channel and read about health more easily : /supply/article/45171 Keywords: Weirimar, Lin Shangwei, AbbVie, Allegra, medical aesthetics, eye care